EGFR antibody (pTyr1125)
Quick Overview for EGFR antibody (pTyr1125) (ABIN358328)
Target
See all EGFR AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- pTyr1125
-
Specificity
- This antibody detects EGFR pTyr1125.
-
Purification
- Protein A Affinity Chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1125 of human EGFR.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Dot Blot: 1/100-1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) Sodium Azide as preservative.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- EGFR (Epidermal Growth Factor Receptor (EGFR))
-
Alternative Name
- EGFR / ERBB1
-
Background
- EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1
-
Molecular Weight
- 134277 Da
-
Gene ID
- 1956, 9606
-
UniProt
- P00533
-
Pathways
- NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins
Target
-